Dataset Information

Chromium(III) substitution inhibits the Fe(II)-accelerated transformation of schwertmannite.

ABSTRACT: Schwertmannite is an Fe(III)-oxyhydroxysulfate which is common in acid mine drainage (AMD) and acid sulfate soil (ASS) environments. Natural schwertmannite is often enriched in Cr(III), yet the effects of Cr(III) substitution on schwertmannite transformation to more stable Fe(III) minerals has not been addressed. Here we examine, for the first time, the effects of Cr(III) substitution on the Fe(II)-accelerated transformation of schwertmannite. X-ray diffraction (XRD) and Fe K-edge extended X-ray absorption fine structure (EXAFS) spectroscopy shows that Cr(III) substitution inhibits schwertmannite transformation. Substitution at a Cr(III):Fe(III) ratio of 0.025 decreased schwertmannite transformation (at pH 6.5) by 18-49% (depending on Fe(II) concentrations) relative to that of Cr(III)-free schwertmannite. Formation of crystalline secondary phases (predominantly goethite) caused associated decreases in solid-phase Fe and Cr extractability by 1 M HCl. The extractability of Cr was consistently greater than that of Fe, suggesting some accumulation of Cr(III) at the residual schwertmannite surface-a phenomenon which passivates the surface against Fe(II)/Fe(III) electron transfer and atom exchange required for the Fe(II)-accelerated transformation process. The finding that Cr(III)-substitution inhibits schwertmannite transformation implies that it may also significantly impact associated Fe, S and trace metal(loid) behaviour.

SUBMITTER: Choppala G

PROVIDER: S-EPMC6281269 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Chromium(III) substitution inhibits the Fe(II)-accelerated transformation of schwertmannite.

Choppala Girish G Burton Edward D ED

PloS one 20181205 12

Schwertmannite is an Fe(III)-oxyhydroxysulfate which is common in acid mine drainage (AMD) and acid sulfate soil (ASS) environments. Natural schwertmannite is often enriched in Cr(III), yet the effects of Cr(III) substitution on schwertmannite transformation to more stable Fe(III) minerals has not been addressed. Here we examine, for the first time, the effects of Cr(III) substitution on the Fe(II)-accelerated transformation of schwertmannite. X-ray diffraction (XRD) and Fe K-edge extended X-ray ...[more]

PMID: 30517205

Similar Datasets

Project description:Rationale: Chemodynamic therapy (CDT) based on the Fe(II)-mediated Fenton reaction is an emerging tumor treatment strategy. However, the catalytic efficiency in tumors is crucially limited by Fe(II). Herein, an endogenous hydrogen sulfide (H2S) accelerated Fe(III)/Fe(II) transformation and photothermal synergistically enhanced CDT strategy based on ellagic acid-Fe-bovine serum albumin (EA-Fe@BSA) nanoparticles (NPs) was developed for colon tumor inhibition. On the one hand, the Fe(III) with low catalytic activity in the EA-Fe@BSA NPs could be rapidly reduced to the highly active Fe(II) by the abundant H2S in colon cancer tissues. Thus, a rapid Fe(III)/Fe(II) conversion system was established, wherein highly active Fe(II) ions were continuously regenerated to improve the CDT efficiency. On the other hand, the photothermal effect of EA-Fe@BSA NPs also accelerated the production of hydroxyl radicals (•OH), thereby synergistically enhancing the CDT performance and improving the therapeutic efficacy. Methods: The endogenous H2S accelerated Fe(III)/Fe(II) conversion and PTT enhanced CDT were investigated by characterization of the Fe valence state and detection of •OH. T 1-weighted magnetic resonance imaging (MRI) was tested both in vitro and in vivo. The biocompatibility of NPs were examined via MTT assay, hemolysis analysis and routine blood measurements. The enhanced CDT was investigated in HCT116 colon cancer cells by Calcein-AM/PI staining and MTT assay, and tumor inhibition was demonstrated in HCT116 tumor bearing mice. Results: In this work, EA-Fe@BSA NPs were constructed as a CDT theranostic reagent. The H2S accelerated Fe(III)/Fe(II) conversion was confirmed, more degradation of MB and generation of •OH demonstrated the enhanced CDT in vitro. EA-Fe@BSA NPs exhibited good T 1-weighted MRI performance. More importantly, it displayed strong near-infrared (NIR) absorption and excellent photothermal efficiency, further promotes the production of •OH. Hence, the efficacy of CDT was enhanced, and the tumor growth was inhibited efficiently. Conclusion: All results demonstrate that this strategy based on endogenous H2S promoted Fe(III)/Fe(II) transformation together with PTT acceleration permits efficient Fenton-reaction- mediated CDT both in vitro and in vivo, which holds great potential for effective colon cancer theranostics.

Dataset Information

Chromium(III) substitution inhibits the Fe(II)-accelerated transformation of schwertmannite.

Publications

Chromium(III) substitution inhibits the Fe(II)-accelerated transformation of schwertmannite.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets